3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
2
Phase EARLY_PHASE1
1
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Oesophagogastric Cancer
1
Inflammatory Breast Neoplasms
1
Carcinoma, Ductal, Breast
1
Breast Diseases
1
Interventions
Gemcitabine
6
Carboplatin
3
valrubicin
2
Cisplatin
2
vinflunine
1
toripalimab
1
pertuzumab
1
disitamab vedotin
1
cabazitaxel
1
apaziquone
1
XRP6258
1
Watchful Waiting
1
Vinblastine
1
Trastuzumab
1
Transurethral Resection of Bladder
1
Tranexamic Acid
1
Saline Solution
1
RC48 antibody
1
Oncolytic Virotherapy
1
Mitomycin
1
Methotrexate
1
Magnetic Resonance Spectroscopy
1
Lapatinib
1
Interferons
1
Interferon-alpha
1
Gabapentin
1
Circulating Tumor DNA
1
Celecoxib
1
BCG Vaccine
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Urinary Bladder Neoplasms
×
Lapatinib
×
Clear all
NCT00949455
2015-04-15
LaMB
Queen Mary University of London
Phase 2/3
Unknown
204 enrolled